Effectiveness and risk of second primary malignancies after radiotherapy in major salivary gland carcinomas: A retrospective study using SEER database.
Head Neck
; 46(5): 1201-1209, 2024 05.
Article
in En
| MEDLINE
| ID: mdl-38284127
ABSTRACT
OBJECTIVE:
To investigate the effectiveness of radiotherapy and its association with second primary malignancies (SPMs) risk in major salivary gland carcinomas (MSGCs) patients.METHODS:
Cohort 1 included 7274 surgically treated MSGC patients from the Surveillance, Epidemiology, and End Results database, assessing the effectiveness of radiotherapy. Cohort 2 (n = 4213) comprised patients with ≥5-year survival in Cohort 1 to study SPMs.RESULTS:
Radiotherapy decreased overall survival in MSGCs patients, but improved it in high-grade MSGCs. Cumulative SPMs incidences at 25 years were 16.5% in the radiotherapy (RT) group compared to 14.5% in the non-radiotherapy (NRT) group. For second head and neck carcinomas (SHNCs), incidences were 3.4% in RT versus 1.6% in NRT. Radiotherapy increased the relative risks of tumors, particularly SHNCs (RR = 1.78). The 10-year OS rates of SHNCs after radiotherapy were significantly lower.CONCLUSION:
Radiotherapy improves survival in advanced-stage MSGCs but increases the risk of developing SPMs, particularly SHNCs.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Salivary Gland Neoplasms
/
Carcinoma
/
Neoplasms, Second Primary
/
Head and Neck Neoplasms
Type of study:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Head Neck
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
United States